Amicus Therapeutics Story

Amicus Therapeutics Inc -- USA Stock  

USD 15.78  0.12  0.75%

Macroaxis does not monitor all media channels or aggregates social signals for Amicus Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Amicus Therapeutics Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Amicus Therapeutics. Additionally see Amicus Therapeutics Hype Analysis, Amicus Therapeutics Correlation and Amicus Therapeutics Performance
Acquisition by Hung Do of 29803 shares of Amicus Therapeutics subject to Rule 16b-3
Filed transaction by Amicus Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Amicus Therapeutics Inc insider trading alert for grant of common stock by Hung Do, Chief Science Officer, on January 3, 2018. This event was filed by Amicus Therapeutics Inc with SEC on 2018-01-05. Statement of changes in beneficial ownership - SEC Form 4. Hung Do is currently serves as senior vice president - discovery biology of Amicus Therapeutics Inc

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.47% . The overall trading delta when the story was published against the current closing price is 2.49% .

Similar stores for Amicus Therapeutics

few hours ago at 
Acquisition by Jay Barth of 762 shares of Amicus Therapeutics subject to Rule 16b-3
Macroaxis News
Filed transaction by Amicus Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3
few days ago at 
A New Kind of Stock Chart Amicus Therapeutics Inc Critical ...
This is a real time view of the critical technical pivot points for Amicus Therapeutics Inc . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.
over a week ago at 
Buy Healthcare Stock analysis Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. stock price traded with dropping change along with the volume 4.42 million shares on Monday trading session.

Did you try this?

Run Idea Optimizer Now

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Hide  View All  NextLaunch Idea Optimizer

Price to Sales

Price to Sales Comparative Analysis
Amicus Therapeutics is currently under evaluation in price to sales category among related companies. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.